Multiple Tumor Types

« Previous 12345 Next »
Viewing Page 1 of 7 | Showing Results 1 - 10 of 67

Molecular Analysis for Therapy Choice (MATCH)

This phase II trial studies how well treatment that is directed by genetic testing works in patients with solid tumors or lymphomas that have...

Alison Conlin, M.D.

The Pacific Cancer Research Consortium clinical trials are offered at multiple locations throughout Oregon, Montana, Washington, Alaska, California, and Idaho. To find a location near you, please contact the Patient Engagement Center at 844-552-2734.

A PHASE 1B/2 STUDY TO EVALUATE SAFETY AND ANTI-TUMOR ACTIVITY OF AVELUMAB IN COMBINATION WITH THE POLY (ADENOSINE DIPHOSPHATE [ADP]-RIBOSE) POLYMERASE (PARP) INHIBITOR TALAZOPARIB IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC SOLID TUMORS

Avelumab in combination with talazoparib will be investigated in patients with locally advanced (primary or recurrent) or metastatic solid tumors,...

Diana Hanna, M.D.
  • Hoag Research
  • xSJH Southern California

The Targeted Agent and Profiling Utilization Registry (TAPUR) Study

The Targeted Agent and Profiling Utilization Registry (TAPUR) Study is a non-randomized clinical trial that aims to describe the safety and...

Walter Urba, M.D., Ph.D.
  • Oncology and Hematology Care Westside
  • Providence Cancer Institute Clackamas Clinic
  • Providence Cancer Institute Franz Clinic
  • Providence Cancer Institute Newberg Clinic

QUILT-3.055: A Phase 2b, Multicohort, Open-Label Study of Combination Immunotherapies in Patients who have Previously Received Treatment with PD-1/PD-L1 Immune Checkpoint Inhibitors

This is a Phase IIb, single-arm, multicohort, open-label multicenter study of ALT-803 in combination with an FDA-approved PD-1/PD-L1 checkpoint...

Rom Leidner, M.D.
  • Providence Cancer Institute Franz Clinic

Implementing a Virtual Tobacco Treatment in Community Oncology Practices: Smoke Free Support Study 2.0.

This phase II trial studies how well smoking cessation treatment plans work in tobacco-dependent cancer patients when delivered virtually as part...

Alison Conlin, M.D.

The Pacific Cancer Research Consortium clinical trials are offered at multiple locations throughout Oregon, Montana, Washington, Alaska, California, and Idaho. To find a location near you, please contact the Patient Engagement Center at 844-552-2734.

A Phase 1b Dose-Escalation Study of Cabozantinib (XL184) Administered Alone or in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors (COSMIC-021)

This is a multicenter Phase 1b, open-label study to assess safety, tolerability, preliminary efficacy, and pharmacokinetics (PK) of cabozantinib...

Matthew Taylor, M.D.
  • Oncology and Hematology Care Westside
  • Providence Cancer Institute Franz Clinic
  • Providence Cancer Institute Newberg Clinic

A Phase 1, Multicenter, Open-Label, Dose Escalation and Dose Expansion Study of SQZ-PBMC-HPV as Monotherapy and in Combination with Atezolizumab in HLA-A*02+ Patients with HPV16+ Recurrent, Locally Advanced or Metastatic Solid Tumors

This is a Phase 1 open-label, multicenter study of the safety and tolerability, immunogenic effects, antitumor activity, and pharmacodynamics of...

Matthew Taylor, M.D.
  • Providence Cancer Institute Franz Clinic

An Open-Label, Non-Randomized, Multicenter Study to Determine the Pharmacokinetics and Safety of Niraparib Following A Single Oral Dose in Patients with Advanced Solid Tumors and Either Normal Hepatic Function or Moderate Hepatic Impairment

Evaluate pharmacokinetics of the study drug. Evaluate the safety of the study drug, niraparib, in cancer patients with moderate hepatic impairment.

Diana Hanna, M.D.
  • Hoag Research
  • xSJH Southern California

Caris Molecular Intelligence® and Caris Centers of Excellence for Precision Medicine NetworkTM Outcomes Associated Repository

a research repository (a database of information), which will be used for research studies to evaluate how clinical outcomes relate to Caris...

Michael Demeure, M.D.
  • Hoag Research
  • xSJH Southern California

A Phase I/2a Dose Escalation and Cohort Expansion Study of the Safety, Tolerability, and Efficacy of Anti-LAG-3 Monoclonal Antibody (BMS-986016) Administered Alone and in Combination With Anti-PD-1 Monoclonal Antibody (Nivolumab, BMS-936558) in Advanced Solid Tumors

The purpose of this study is to assess the safety and tolerability, characterize the dose-limiting toxicities, and identify the maximum tolerated...

Rachel Sanborn, M.D.
  • Providence Cancer Institute Franz Clinic
« Previous 12345 Next »
Viewing Page 1 of 7 | Showing Results 1 - 10 of 67